KR101972333B1 - 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 - Google Patents
섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 Download PDFInfo
- Publication number
- KR101972333B1 KR101972333B1 KR1020170099669A KR20170099669A KR101972333B1 KR 101972333 B1 KR101972333 B1 KR 101972333B1 KR 1020170099669 A KR1020170099669 A KR 1020170099669A KR 20170099669 A KR20170099669 A KR 20170099669A KR 101972333 B1 KR101972333 B1 KR 101972333B1
- Authority
- KR
- South Korea
- Prior art keywords
- polynucleotide
- fibromyalgia
- snp
- present
- snps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002493 microarray Methods 0.000 title claims description 20
- 208000001640 Fibromyalgia Diseases 0.000 title abstract description 55
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 60
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 60
- 239000002157 polynucleotide Substances 0.000 claims abstract description 60
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 230000000295 complement effect Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims description 7
- 208000000112 Myalgia Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 208000013465 muscle pain Diseases 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 abstract description 19
- 102100033902 Endothelin-1 Human genes 0.000 abstract description 9
- 101800004490 Endothelin-1 Proteins 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 2
- 239000002299 complementary DNA Substances 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 238000011308 HRM-sequencing Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000013173 literature analysis Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
도 2는 HRM염기서열분석법을 통해 분석된 엔도세린-1 SNP의 단일염기다형성의 결과 그래프.
SNP의 NCBI 젠뱅크등록번호 |
SNP가 포함된 폴리뉴클레오티드 | 유전자 | SNP 역할 | 대립 유전자 |
rs1800541 |
서열번호1 |
endothelin 1 |
promoter |
T/G |
SNP | Position | Forward primer sequence | Reverse primer sequence | PCR product sizw(bp) |
Alleles |
T-1370G (rs1800541) |
12228986 |
5'-CAG AAT GAC CCC GTG ACA C-3' | 5'-CAT TGG CTT TTT CCG CTA GC-3' | 120 |
G/T |
유전형/대립유전자 | 정상군 (n=87) | 섬유근육통 (n=88) | 모델 | OR (95% CI) | P | ||
Freq. | % | Freq. | % | ||||
TT | 55 | 63.20 | 35 | 39.80 | Co-dominant | 3.14(1.59-6.23) | 0.004 |
TG | 20 | 23.00 | 40 | 45.50 | 1.70(0.70-4.15) | ||
GG | 12 | 13.80 | 13 | 14.80 | Dominant | 2.60(1.41-4.79) | 0.002 |
Recessive | 1.08(0.46-2.53) | 0.850 | |||||
T | 130 | 0.75 |
110 | 0.62 | |||
G | 44 | 0.25 |
66 | 0.38 | 0.56(0.36-0.89) | 0.014 | |
FMS, fibromyalgia syndrome; Freq., frequency; OR, odds ratio; CI, confidence intervals; P, p-value. |
Claims (5)
- 엔도세린-1 유전자의 일부를 구성하는 서열번호 1의 폴리뉴클레오티드의 rs1800541에 해당하는 501번째 염기를 포함하면서 8개 이상의 연속 염기로 구성되는 폴리뉴클레오티드 또는 그의 상보적 폴리뉴클레오티드를 포함하는 한국인의 섬유근육통 진단용 조성물.
- 삭제
- 엔도세린-1 유전자의 일부를 구성하는 서열번호 1의 폴리뉴클레오티드의 rs1800541에 해당하는 501번째 염기를 포함하면서 8개 이상의 연속 염기로 구성되는 폴리뉴클레오티드 또는 그의 상보적 폴리뉴클레오티드를 포함하는 한국인의 섬유근육통 진단용 마이크로어레이.
- 제3항에 있어서,
상기 폴리뉴클레오티드는 아미노-실란, 폴리-L-라이신 및 알데히드로 이루어진 군에서 선택되는 활성기가 코팅된 기판에 고정되는 것을 특징으로 하는 한국인의 섬유근육통 진단용 마이크로어레이. - 제3항 또는 제4항의 마이크로어레이를 포함하는 한국인의 섬유근육통 진단용 키트.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170099669A KR101972333B1 (ko) | 2017-08-07 | 2017-08-07 | 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170099669A KR101972333B1 (ko) | 2017-08-07 | 2017-08-07 | 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190015900A KR20190015900A (ko) | 2019-02-15 |
KR101972333B1 true KR101972333B1 (ko) | 2019-04-25 |
Family
ID=65367314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170099669A Active KR101972333B1 (ko) | 2017-08-07 | 2017-08-07 | 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101972333B1 (ko) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100708486B1 (ko) | 2005-07-19 | 2007-04-18 | 이행우 | 섬유근육통증후군의 증상 개선 및 예방용 조성물 |
MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
-
2017
- 2017-08-07 KR KR1020170099669A patent/KR101972333B1/ko active Active
Non-Patent Citations (4)
Title |
---|
Molecular and Cellular Toxicology (2016) 12:111-116 |
NCBI, dbSNP: ss278656616 (2010.12.16.) |
NCBI, GenBank: J05008.1 (1994.11.07.) |
Rheumatology (2003) 42:493-494* |
Also Published As
Publication number | Publication date |
---|---|
KR20190015900A (ko) | 2019-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008534009A (ja) | 大腸癌診断用の多重snp、それを含むマイクロアレイ及びキット、並びにそれを利用した大腸癌の診断方法 | |
US20060263815A1 (en) | Multiple SNP for diagnosing cardiovascular disease, microarray and kit comprising the same, and method of diagnosing cardiovascular disease using the same | |
KR100754398B1 (ko) | 심혈관 질환 진단용 다중 snp, 그를 포함하는마이크로어레이 및 키트 및 그를 이용한 심혈관 질환 진단방법 | |
KR101523769B1 (ko) | 허혈성 뇌졸중 진단용 다중 snp 및 이의 용도 | |
KR101972333B1 (ko) | 섬유근육통 진단용 조성물, 그를 포함하는 마이크로어레이 및 키트 | |
CN101294201A (zh) | 冠心病检测方法和试剂盒 | |
KR101203353B1 (ko) | 양극성 장애 진단용 프로브 조성물 및 이를 이용하여 양극성 장애를 진단하는 방법 | |
KR100908125B1 (ko) | 심근 경색에 관련된 유전자 다형성 및 그의 용도 | |
KR100790871B1 (ko) | 심근 경색에 관련된 유전자 다형성 및 그의 용도 | |
KR102409336B1 (ko) | 면역글로불린 a 신병증 및 혈관염 진단용 snp 마커 및 이를 이용한 진단 방법 | |
CN101294198A (zh) | 冠心病检测方法和试剂盒 | |
CN101294197A (zh) | 冠心病检测方法和试剂盒 | |
KR101058583B1 (ko) | 뇌경색 진단용 다중 snp, 및 이를 포함하는 마이크로어레이 및 키트 | |
KR100912472B1 (ko) | 정신분열증 진단용 snp와 초위성체, 그를 포함하는마이크로어레이 및 키트 | |
US20060257913A1 (en) | Genetic polymorphisms associated with myocardial infarction and uses thereof | |
KR100912470B1 (ko) | 정신분열증 진단용 snp와 그를 포함하는 마이크로어레이및 키트 | |
KR100912469B1 (ko) | 정신분열증 진단용 snp와 그를 포함하는 마이크로어레이및 키트 | |
KR20060117691A (ko) | 대상의 유형에 따른 심혈관 질환 진단용 snp, 그를포함하는 마이크로어레이 및 키트 및 그를 이용한 심혈관질환 진단 방법 | |
CN101294210A (zh) | 冠心病检测方法和试剂盒 | |
CN101294200A (zh) | 冠心病检测方法和试剂盒 | |
CN101294199A (zh) | 冠心病检测方法和试剂盒 | |
CN101294214A (zh) | 冠心病检测方法和试剂盒 | |
KR20120001916A (ko) | 아스피린 과민성 천식의 진단용 snp 유전자 세트 | |
CN101294209A (zh) | 冠心病检测方法和试剂盒 | |
CN101294203A (zh) | 冠心病检测方法和试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170807 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180706 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190120 |
|
PG1501 | Laying open of application | ||
PN2301 | Change of applicant |
Patent event date: 20190320 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190419 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20190419 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20220513 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20230222 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20240215 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20250305 Start annual number: 7 End annual number: 7 |